Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko AA, Pop OT, Ighilahriz M, Padioleau I, Rajabi F, Sharpe HJ, Poulalhon N, Dreno B, Khammari A, Delord M, Alberti A, Soufir N, Battistella M, Mourah S, Bouquet F, Savina A, Besse A, Mendez-Lopez M, Grange F, Monestier S, Mortier L, Meyer N, Dutriaux C, Robert C, Saiag P, Herms F, Lambert J, de Sauvage FJ, Dumaz N, Flatz L, Basset-Seguin N, Nikolaev SI. Yurchenko AA, et al. Among authors: savina a. Clin Cancer Res. 2022 Apr 1;28(7):1422-1432. doi: 10.1158/1078-0432.CCR-21-3764. Clin Cancer Res. 2022. PMID: 35078858 Free PMC article.
Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
Ighilahriz M, Benfodda M, Sharpe H, Soufir N, Mourah S, Dumaz N, Battistella M, Savina A, Bouquet F, Nikolaev S, Basset-Seguin N. Ighilahriz M, et al. Among authors: savina a. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e422-e424. doi: 10.1111/jdv.15741. Epub 2019 Jul 15. J Eur Acad Dermatol Venereol. 2019. PMID: 31187903 No abstract available.
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.
Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A. Frazao A, et al. Among authors: savina a. Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2. Cancer Immunol Res. 2017. PMID: 28576831
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R. Rodallec A, et al. Among authors: savina a. Anticancer Drugs. 2020 Jun;31(5):463-472. doi: 10.1097/CAD.0000000000000878. Anticancer Drugs. 2020. PMID: 31895102
Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.
Corazao-Rozas P, Guerreschi P, Jendoubi M, André F, Jonneaux A, Scalbert C, Garçon G, Malet-Martino M, Balayssac S, Rocchi S, Savina A, Formstecher P, Mortier L, Kluza J, Marchetti P. Corazao-Rozas P, et al. Among authors: savina a. Oncotarget. 2013 Nov;4(11):1986-98. doi: 10.18632/oncotarget.1420. Oncotarget. 2013. PMID: 24161908 Free PMC article.
131 results